PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).

ATXA Therapeutics has developed NTP42, a disruptive new drug for pulmonary arterial hypertension (PAH) and related cardiopulmonary (heart & lung) diseases. NTP42 blocks the thromboxane receptor, a target at the root cause of PAH & related diseases.

By treating all clinical hallmarks in both the LUNGS and HEART, NTP42 offers a game-changing solution for PAH leading to its rapid adoption once marketed.

ATXAs Phase I clinical trial showed NTP42 is safe & highly efficacious in man.With EIC Blended Finance and VC co-investment, ATXA will undertake a Phase II trial on NTP42 in PAH.

We will then secure a licensing deal with a pharma to ACCELERATE NTP42 to the PAH market (sales >$1B at 5 yrs post-launch & royalty returns to ATXA).

With the proceeds of the licensing deal, we will DIVERSIFY uses of NTP42/pipeline drugs to treat other priority target diseases.

This will also ENABLE growth (>100 FTEs), transforming ATXA into a major European pharma with a diversified diseases & drugs portfolio.